Loading...
Market
What will be 23andMe's market share change in consumer genetics by end of 2025?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No change • 25%
Decrease • 25%
Industry reports from market research firms like IBISWorld or Statista
Story
23andMe Cuts 40% of Workforce, Ends Drug Development
Nov 12, 2024, 12:08 AM
23andMe, a genetic testing firm, has announced a significant restructuring program that includes reducing its workforce by approximately 40%, affecting over 200 employees, and discontinuing its drug development efforts. The company aims to streamline operations, reduce costs, and focus on its consumer genetics business. This restructuring will incur one-time costs of up to $12 million.
View original story
Similar markets
Below 5% • 25%
5%-10% • 25%
10%-15% • 25%
Above 15% • 25%
Ancestry services • 25%
Health-related genetics services • 25%
Personalized wellness products • 25%
Other • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Genetic Testing • 25%
Health and Wellness • 25%
Data Licensing • 25%
Other • 25%
Outperforms competitors • 25%
Matches competitors • 25%
Underperforms competitors • 25%
Significantly underperforms competitors • 25%
